Drug Search Results
More Filters [+]

Thyroglobulin

Alternative Names: thyroglobulin
Latest Update: 2024-05-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Tubulin Inhibitor

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Chile | China | India

Approved Indications: None

Known Adverse Events: None

Company: Shanghai tenth People's Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Thyroglobulin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Thyroid Cancer

Phase 1: Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SCRC21021CTIL

N/A

Recruiting

Thyroid Cancer|Lymphatic Metastasis

2024-12-31

ChiCTR2000036620

N/A

Not yet recruiting

Thyroid Cancer

2023-12-31

ChiCTR2200055183

N/A

Recruiting

Thyroid Cancer

2023-01-30

NCI-2015-01781

P1

Terminated

Oncology Solid Tumor Unspecified|Oncology Hematological Unspecified

2020-07-01

Recent News Events